Skip to main content

Table 1 MK-2206 treatment regimen by treatment arm

From: Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

Treatment arm MK-2206 dose, mg Schedulea Combination with:
1 45 QOD Carboplatin (IV, AUC6, 1-hour infusion) and paclitaxel (IV, 200 mg/m2, 3-hour infusion)
60
90 Q3W
135
200
2 45 QOD Docetaxel (IV, 75 mg/m2, 1-hour infusion)
90 Q3W Docetaxel (IV, 60 mg/m2, 1-hour infusion)
135
200
3 45 QOD* Erlotinib (oral, 100 mg, QD)
45 Erlotinib (oral, 150 mg, QD)
135 QW Erlotinib (oral, 100 mg, QD)
  135   Erlotinib (oral, 150 mg, QD)
  1. Abbreviations: IV intravenous, AUC6 area under the curve 6.0 mg/mL, QD once daily.
  2. aQOD = once every other day on days 1, 3, 5, and 7 of 21-day cycle, except *: alternate day dosing on days 1–21; Q3W = once every 3 weeks on day 1 of 21-day cycle; QW = once weekly on days 1, 8, and 15 of 21-day cycle.